4582 — SymBio Pharmaceuticals Balance Sheet
0.000.00%
- ¥8bn
- ¥4bn
- ¥2bn
Annual balance sheet for SymBio Pharmaceuticals, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 3,849 | 3,860 | 6,283 | 6,517 | 3,964 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 722 | 2,148 | 2,085 | 913 | 423 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 5,815 | 6,748 | 9,313 | 8,083 | 4,924 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 76.7 | 83.6 | 69 | 0 | 0 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 6,275 | 8,453 | 10,433 | 8,170 | 4,968 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,615 | 1,518 | 1,924 | 957 | 766 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,617 | 1,707 | 1,927 | 960 | 771 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 4,657 | 6,746 | 8,506 | 7,210 | 4,198 |
Total Liabilities & Shareholders' Equity | 6,275 | 8,453 | 10,433 | 8,170 | 4,968 |
Total Common Shares Outstanding |